NASDAQ
39.91USD
-1.26 (-3.07%)
We have scored 4 news catalysts on Edgewise Therapeutics, Inc. (EWTX) over the past 12 months. The biggest single-day move next to one of them came Dec 24, 2025, when EWTX closed +25.5%: “Why Edgewise Therapeutics Stock Rocked the Market Today”. Coverage across the window leans positive (average ticker sentiment +0.93). Most of the impact sits in institutional appeal and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.3B
P/E
—
EPS
—
Beta
0.28
52W range
19.76-48.78
Day range
39.73–41.40
Open
40.81
Prev close
41.17
Volume
1.2M
Avg volume
1.4M
Dividend
0.00
IPO
2021-03-26
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Edgewise Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for EWTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.